Research programme: stem cell-derived retina transplant - AIVITA Biomedical
Latest Information Update: 17 Nov 2021
At a glance
- Originator AiVita Biomedical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Retinal disorders
Most Recent Events
- 02 Nov 2021 Preclinical trials in Retinal disorders in USA (AIVITA Biomedical website, November 2021)
- 02 Nov 2021 Pharmacodynamics data from a preclinical trial in Retinal disorders released by AIVITA Biomedical (AIVITA Biomedical website, November 2021)